Warsaw 2013 Programme Registration Exhibition Hotels Virtual Exhibition Warsaw Satellite Meetings Visa Information

Cell / flare in the anterior chamber after implantation of the Alcon AcrySof cachet

Poster Details

First Author: S.Taneri GERMANY

Co Author(s):    S. Oehler   C. Heinz           

Abstract Details


Moderately or highly myopic eyes not deemed suitable for laser vision correction may be eligible for implantation of an anterior chamber intraocular lens for vision correction. However, with other phakic intraocular lenses this has been associated with anterior chamber inflammation. We wanted to quantify the response to a new foldable acrylic lens model over time.


: Zentrum für Refraktive Chirurgie, Augenabteilung am St. Franziskus Hospital Münster, Germany


Prospective study of adult patients with stable myopia >7 D, who were not eligible for full correction with an excimer laser. Exclusion criteria: Anterior chamber depth <3.2mm (measured including corneal thickness), insufficient endothelial cell density according to manufacturer’s age-related recommendations, other pre-existing ocular conditions, and prior eye surgery. Slitlamp examination and laser flare photometry before and 1 day, 1 week, 1 month, 3 months, and 12 months after implantation of an Alcon Acrysof Cachet lens. Postop treatment includes antibiotic eye-drops for 5 days and non-steroidal anti-inflammatory eye-drops for 4 weeks.


In our patients preop laser cell flare values were 6.45 (range 1.80 to 40.40) photons/ms, postop laser cell flare values were 20.25 (range 2.50 to 148.40)/ 20.81 (range 4.70 to 114.90)/ 14.19 (range 2.50 to 48.60)/ 12.68 (range 2.50 to 63.90)/ 8.11 (range 1.10 to 20.40) photons/ms 1 day/ 1 week/ 1 month/ 3 months/ 12 months after implantation of the Acrysof Cachet, respectively.


Results indicate a low maximum inflammatory response in the anterior chamber and a relative quick recovery of laser cell flare counts to safe values. An anti-inflammatory prophylaxis with non-steroidal eye-drops seems sufficient in routine cases. Thus the potential drawbacks of corticoid therapy may be avoided.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to previous